Histologically, VMs appear irregular with a flattened endothelium and a thin basement membrane. 1, 2 All VMs are present at birth, but often manifest clinically between infancy and early adulthood. VMs grow as children develop, and are associated with a wide range of symptoms based on their localization and size. Most patients experience localized intravascular coagulopathy that may lead to thrombosis and pain. Symptoms can be exacerbated by trauma or altered hormonal states (puberty, pregnancy). 2, 5 In larger lesions, the associated thrombophilic profile of VMs also predisposes patients to deep venous thrombosis and pulmonary embolism. Management of VMs includes pressure garments, pain medication and prophylactic heparin during states of increased risk for thrombosis (pregnancy, prolonged bed rests, surgery). Treatments are indicated if a lesion causes severe pain, functional impairment or aesthetic concerns, and include intervention radiology with sclerotherapy or surgical resection. Importantly, surgical resection is contraindicated if VMs interact with critical neurovascular structures. The efficacy of sclerotherapy depends on the sclerosant used. 2 Most sclerosants used for VMs (ethanol, or surfactants such as sodium tetradecylsulfate or polidocanol) trigger necrosis-mediated vessel destruction. 2 Ethanol is the most efficient agent but also the most toxic. Side-effects of sclerotherapy, which include skin necrosis and nerve injury at the site of injection, can affect up to 30% of treated patients. 2 With the choice of sclerosant being the most important variable for complications, research aimed at identifying efficient therapies with fewer side-effects is of great clinical interest. In this issue of the British Journal of Dermatology, Ren et al. sought to gain insight into the pathology of VMs by analysing the expression pattern of CCN proteins in human VM samples. 6 CCNs form a family of six proteins named after their first three members [Cyr61 is CCN1; connective tissue growth factor is CCN2; and nephroblastoma overexpressed (Nov) is CCN3]. CCNs are multimodular, matricellular proteins involved in a plethora of biological functions encompassing embryogenesis, inflammation, fibrosis and tumorigenesis. 7, 8 Ren et al. found that CCN2 levels are reduced in VMs compared with normal skin blood vessels. The authors also show colocalization of CCN2 with the profibrotic transforming growth factor (TGF)b in human cutaneous blood vessels, and underscore a significant correlation between reduced CCN2 protein and reduction of TGFb and perivascular a-smooth muscle actin levels in VMs. These results, suggestive of an association between the TGFb/CCN2 pathway and vascular integrity in human skin, are consistent with previous work identifying CCN2 as a critical endothelial organizer, a mediator of vascular basement membrane production in mice, 9 and a downstream effector of TGFb-mediated extracellular matrix production. 10 Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis (TOACS), in which 1271 adolescents with a mean age of 14 years had originally been enrolled. A response rate of 75% was achieved in the questionnaire follow-up. Keeping loss to follow-up low is important for any prospective cohort study to avoid the reporting of biased results. The study is important because it is the first to report on the epidemiology of hand eczema (HE) from adolescence to adulthood in an unselected population. The first aim of the study was to estimate the incidence of HE from adolescence to adulthood, i.e. the number of newly occurring cases of HE in the observation period. An incidence rate of 8Á8 per 1000 persons per year was estimated. The period from adolescence to adulthood is critical for the development of HE, and it is this period in which occupational choices are made and some young adults will choose occupations carrying an elevated risk of developing HE. Previous studies reporting incidence data have either been limited to adult populations 2,3 or have followed up selected populations of adolescents such as car industry apprentices. 4 The second aim was to estimate HE prevalence, which is important in order to understand the population burdened with the disease. The point, 1-year-period and lifetime prevalence rates were estimated at 7Á1%, 14Á4% and 23Á0%, respectively. A review of epidemiological studies on HE, including seven population-based studies, reported lower estimates for incidence (5Á5 cases per 1000
person-years) and point, 1-year-period and lifetime prevalence rates (4Á0%, 10% and 15%, respectively). 5 This reflects the younger age group investigated in TOACS and demonstrates that the onset and burden of HE are particularly high in adolescents and young adults. Both the TOACS follow-up and the review found incidence and prevalence estimates to be substantially higher in women than men. The third aim of Moertz et al. was to investigate risk factors for HE in the past year in the young adults who were followed up, applying logistic regression modelling. Studying risk factors for HE is important in order to identify those modifiable factors that act in concert with constitutional factors, but are therefore amenable to prevention and/or early treatment. The significant positive associations of childhood atopic dermatitis with HE in adolescence 3, 6 and taking care of small children with HE, 7 as well as the lack of association of nickel sensitization and HE, 6, 8 have been previously reported. The lack of association of HE with smoking seems to contradict previous findings, 9,10 but the effects of smoking seem to depend on exposure level and may also be restricted to certain subtypes of HE. Although the clinical examination included in the study by Moertz et al.
showed that most cases of HE that were examined were actually mild, it is striking that the chances of sick leave, disability pension or rehabilitation were found to be almost threefold increased with HE, pointing to the potentially severe consequences of HE already in young adults.
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